title: Immunotherapy for cancer: construction, expression and functional characterization of chimeric antibodies.
abstract: Monoclonal antibodies (Mabs) are a potential key component for the treatment of cancer, because of their specificity and multiple effector functions. Hybridoma technology and progress in genetic engineering made it possible to customize antibody molecules, rendering them more suitable for selective application. A widely used technique is the construction of mouse-human hybrid molecules by recombinant DNA techniques. These so-called chimeric antibodies contain the murine variable (V) regions fused to the human constant (C) regions. In this report, a general approach is described for the production of chimeric antibodies. The gene segments encoding the murine variable heavy and light chain are isolated by the polymerase chain reaction and cloned into expression vectors containing the human gamma 1 heavy chain gene and the human K light chain gene, respectively. Subsequently, these constructs are transfected into a non-Ig-producing murine hybridoma, eg SP2/0 cells. The in vitro study of the functional characteristics and biological properties of the thus obtained chimeric antibodies are discussed.
authors.affiliation: Dr L Willems-Instituut, Diepenbeek, Belgium.
authors.forename: K
authors.initials: K
authors.lastname: Motmans
authors.forename: S
authors.initials: S
authors.lastname: Thirion
authors.forename: H
authors.initials: H
authors.lastname: Heyligen
authors.forename: J
authors.initials: J
authors.lastname: Janssens
authors.forename: J
authors.initials: J
authors.lastname: Raus
authors.forename: C
authors.initials: C
authors.lastname: Vandevyver
mesh_terms: D000911:Antibodies, Monoclonal / Q000096:biosynthesis* / Q000627:therapeutic use; D006801:Humans; D006825:Hybridomas; D007127:Immunoglobulin Constant Regions / Q000096:biosynthesis; D007143:Immunoglobulin Heavy Chains / Q000096:biosynthesis; D007147:Immunoglobulin Light Chains / Q000096:biosynthesis; D009369:Neoplasms / Q000276:immunology* / Q000628:therapy*; D016133:Polymerase Chain Reaction / Q000379:methods*; D015375:Receptors, Interleukin-2 / Q000276:immunology*; D011993:Recombinant Fusion Proteins / Q000096:biosynthesis* / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D007127:Immunoglobulin Constant Regions; D007143:Immunoglobulin Heavy Chains; D007147:Immunoglobulin Light Chains; D015375:Receptors, Interleukin-2; D011993:Recombinant Fusion Proteins